Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Glaucoma is the second most common cause of blindness, and without constant vigilance it can prove a very difficult disease to manage. But a Swiss biotech company has developed a monitoring system that allows physicians to keep track of their patients’ symptoms over 24 hours. Sensimed’s “Triggerfish” system consists of a contact lens with embedded sensors that can pick up subtle physical changes in a patient’s eye, and then wirelessly transmit that data to a receiver worn around his neck.

Despite decades of study, researchers still only poorly understand the causes of glaucoma, a group of diseases in which deterioration of the optic nerve can eventually lead to blindness. But controlling one symptom in particular–high intraocular pressure, which is caused by too much liquid inside the eye–appears to help prevent disease progression.

“Nowadays, glaucoma specialists live in the dark,” says Kaweh Mansouri, an ophthalmologist who has been using the Sensimed system in his clinic at the University Hospital, Geneva. “We only get a few chances to see the patient and measure intraocular pressure, and we know this is a major drawback of how we diagnose and treat glaucoma.”

Current methods for glaucoma diagnosis and monitoring are usually limited to single snapshots in time, taken at a visit to the eye doctor during daytime, when pressure tends to be at its lowest. But glaucoma specialists believe that one of the main contributors to disease progression is frequent changes in pressure over the course of a day, or high peaks during the night–something that, in the most serious cases, requires frequent measurement during an overnight hospitalization. The Sensimed device, the first of its kind on the market, provides constant readings for a fraction of the price of a hospital stay. The company received safety approval for Triggerfish in Europe last year, and is hoping for U.S. Food and Drug Administration approval by late 2011.

The Triggerfish lens is made of the same silicon hydrogel as many of the soft contact lenses currently on the market, but embedded within it is a microprocessor and a strain gauge that encircles its outer edge. When fluid accumulates in the eye, the diameter of the cornea changes, and that change is picked up by the strain gauge. Data is processed and then transmitted via radio frequency to a receiver.

In more than one-third of the 50 patients Mansouri has tested, the results led to a direct, immediate change in treatment, he says. If a person’s intraocular pressure peaked at odd hours of the night, for example, he could now detect it and change medication doses to account for that. If prescription drugs didn’t seem to be helping at all, he could change course and try surgery instead. “For the first time, we were able to look into the darkness of glaucoma, and we saw things happening during the night that were surprising,” he says.

0 comments about this story. Start the discussion »

Credit: Sensimed

Tagged: Biomedicine, Business, blindness, chip, contact lens, glaucoma, eyes

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me